Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Double Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater

NCT01198626 is registered in ClinicalTrials.gov with Furiex Pharmaceuticals, Inc as lead sponsor.

NCT NCT01198626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01198626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Double Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater
Lead sponsor
Furiex Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2010
Completion date
October 31, 2011
Enrollment
32 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired bacterial pneumonia (cabp)